drugset / Trial / NCT02286882
A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects
RandomizedParallel-groupTriple-blindBasic science
Summary
PF-06409577 is a new compound proposed for the treatment of diabetic nephropathy. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of PF-06409577 in healthy adult subjects.
Timeline
- Start
- 2014-11
- Primary completion
- 2015-06
- Completion
- 2015-06
Outcome
Outcome not reported
Stopped (Business): “The trial was terminated prematurely on June 19, 2015 for business reasons. There were no safety concerns in the study which led to the decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-06409577 | Unknown | — | Oral |
Indications
No indication recorded.